Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides

Jiao Luo,Meiling Zheng,Bo Jiang,Chao Li,Shuju Guo,Lijun Wang,Xiangqian Li,Rilei Yu,Dayong Shi

DOI: https://doi.org/10.1111/bph.15195

IF: 7.3

2020-08-30

British Journal of Pharmacology

Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background and Purpose</h3><p>Protein tyrosine phosphatase (PTP) 1B (PTP1B) plays a critical role in the regulation of obesity, type 2 diabetes mellitus (T2DM), and other metabolic diseases. However, drug candidates exhibiting PTP1B selectivity and oral bioavailability are currently lacking. Here, the enzyme inhibitory characteristics and pharmacological benefits of BDB were investigated <i>in vitro </i> and <i>in vivo </i>. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Experimental Approach</h3><p>Surface plasmon resonance (SPR) assay was performed to validate the direct binding of BDB to PTP1B, and Lineweaver‐Burk plotting of the enzymatic reaction was used to identify the inhibition type of BDB. Both <i>in vitro </i> enzyme‐inhibition assays and SPR experiments were also conducted to study the selectivity exhibited by BDB toward four other PTP‐family proteins: TC‐PTP, SHP‐1, SHP‐2, and LAR. C2C12 myotubes were used to evaluate BDB cell permeability and effect on insulin signaling, and hypoglycemic and hypolipidemic effects of BDB were investigated in diabetic BKS db mice by using oral gavage. The beneficial effects of BDB on pancreatic islets were examined based on insulin and/or glucagon staining. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key Results</h3><p>BDB acted as a competitive inhibitor of PTP1B and demonstrated high selectivity for PTP1B among the tested PTP‐family proteins. Moreover, BDB was cell permeable and enhanced insulin signaling in C2C12 myotubes. Lastly, oral administration of BDB produced effective antidiabetic effects in spontaneously diabetic mice and markedly improved islet architecture, which was coupled with an increase in the ratio of β‐cells to α‐cells.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusion and Implications</h3><p>BDB application offers a potentially practical pharmacological approach for treating T2DM by selectively inhibiting PTP1B.</p></section>

pharmacology & pharmacy

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop an effective drug for treating type 2 diabetes mellitus (T2DM). Specifically, the researchers aim to verify whether the natural bromophenol compound BDB (3 - bromo - 4,5 - bis(2,3 - dibromo - 4,5 - dihydroxybenzyl)-1,2 - benzenediol) isolated from the red alga Rhodonela confervoides can be a selective inhibitor of protein tyrosine phosphatase 1B (PTP1B), and evaluate its therapeutic effects on diabetes in vitro and in vivo. PTP1B is a protein closely related to obesity and type 2 diabetes, which affects the development of these diseases by down - regulating the tyrosine phosphorylation status of key molecules in the insulin and leptin signaling pathways. Therefore, finding small - molecule inhibitors that can specifically inhibit PTP1B is of great significance for the development of new diabetes treatment methods. The main objectives of the study include: 1. **Confirm the characteristics of BDB as a PTP1B inhibitor**: Verify the direct binding of BDB to PTP1B and its inhibition type through in vitro enzyme inhibition assays and surface plasmon resonance (SPR) technology. 2. **Evaluate the selectivity and cell permeability of BDB**: Determine whether BDB can selectively inhibit PTP1B without affecting other PTP family members and whether it can enter the cell interior to exert its effect through selectivity experiments and cell experiments. 3. **Study the in vivo anti - diabetes effect of BDB**: Using a spontaneous diabetic mouse model (BKS db/db mice), evaluate the effects of BDB on blood glucose levels, blood lipid levels, and islet structure through oral administration. 4. **Explore the clinical application potential of BDB**: Based on the above research results, discuss the possibility of BDB as a potential type 2 diabetes treatment drug. In summary, the goal of this study is to comprehensively evaluate the potential of BDB as a PTP1B inhibitor and provide a scientific basis for its possible future clinical application.

Antidiabetic activity in vitro and in vivo of BDB, a selective inhibitor of protein tyrosine phosphatase 1B, from Rhodomela confervoides

Discovery of Core-Structurally Novel PTP1B Inhibitors with Specific Selectivity Containing Oxindole-Fused Spirotetrahydrofurochroman by One-Pot Reaction.

Identification of natural product inhibitors of PTP1B based on high-throughput virtual screening strategy: In silico, in vitro and in vivo studies

Discovery of 5-(3-bromo-2-(2,3-dibromo-4,5-dimethoxybenzyl)-4,5-dimethoxybenzylidene)thiazolidine-2,4-dione as a novel potent protein tyrosine phosphatase 1B inhibitor with antidiabetic properties

Selectivity, Cell Permeability and Oral Availability Studies of Novel Bromophenol Derivative HPN As Protein Tyrosine Phosphatase 1B Inhibitor

Discovery of Inhibitors Targeting Protein Tyrosine Phosphatase 1B Using a Combined Virtual Screening Approach

Discovery of Bisindole As A Novel Scaffold for Protein Tyrosine Phosphatase 1b Inhibitors

Binding properties of marine bromophenols with human protein tyrosine phosphatase 1B: Molecular docking, surface plasmon resonance and cellular insulin resistance study

BPN, a Marine-Derived PTP1B Inhibitor, Activates Insulin Signaling and Improves Insulin Resistance in C2C12 Myotubes.

Protein tyrosine phosphatase 1B (PTP1B) function, structure, and inhibition strategies to develop antidiabetic drugs

Small Molecules As Potent Protein Tyrosine Phosphatase 1B (PTP1B) Inhibitors Documented in Patents from 2009 to 2013

Natural and semisynthetic protein tyrosine phosphatase 1B (PTP1B) inhibitors as anti-diabetic agents

Improved Glucose-Stimulated Insulin Secretion by Intra-Islet Inhibition of Protein-Tyrosine Phosphatase 1b Expression in Rats Fed A High-Fat Diet

16S rRNA Sequencing and Metagenomics Study of Gut Microbiota: Implications of BDB on Type 2 Diabetes Mellitus

Theoretical study on the design of allosteric inhibitors of diabetes associated protein PTP1B

Discovery of Novel PTP1B Inhibitors by High-throughput Virtual Screening

Design, synthesis, biological evaluation and molecular dynamics simulation studies of imidazolidine-2,4-dione derivatives as novel PTP1B inhibitors

Discovery and Evaluation of the Hybrid of Bromophenol and Saccharide As Potent and Selective Protein Tyrosine Phosphatase 1B Inhibitors

Effect of a Novel Proteoglycan PTP1B Inhibitor from Ganoderma Lucidum on the Amelioration of Hyperglycaemia and Dyslipidaemia in Db/db Mice.

Hypoglycemic effect of the Phellinus baumii extract with α-glucosidase-inhibited activity and its modulation to gut microbiota in diabetic patients

In silico network pharmacology and in vivo analysis of berberine-related mechanisms against type 2 diabetes mellitus and its complications